Back to top

Tale of the Tape

Zacks Equity Research

KemPharm (KMPH) Catches Eye: Stock Adds 9% in Session
October 12, 2016


Trades from $3

KemPharm, Inc. (KMPH - Snapshot Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The upside came after the company announced that its Investigational New Drug (IND) application for KP415 has been accepted by the FDA. This led to solid volume too with far more shares changing hands than in a normal session. Yesterday’s rally breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.36 to $4.69 since Sep 15, 2016.

The company has seen no estimate revisions over the past 30 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

KemPharm currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Med-Drugs industry is Ariad Pharmaceuticals Inc. (ARIA - Analyst Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

Is KMPH going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>